A New Resorufin-based Alpha-glucosidase Assay for High-throughput Screening

Overview

Journal Anal Biochem

Publisher Elsevier

Specialty Biochemistry

Date 2009 Apr 18

PMID 19371716

Citations 11

Authors

Omid Motabar

Zhen-Dan Shi

Ehud Goldin

Ke Liu

Noel Southall

Ellen Sidransky

Christopher P Austin

Gary L Griffiths

Wei Zheng

Affiliations

Soon will be listed here.

Abstract

Mutations in alpha-glucosidase cause accumulation of glycogen in lysosomes, resulting in Pompe disease, a lysosomal storage disorder. Small molecule chaperones that bind to enzyme proteins and correct the misfolding and mistrafficking of mutant proteins have emerged as a new therapeutic approach for the lysosomal storage disorders. In addition, alpha-glucosidase is a therapeutic target for type II diabetes, and alpha-glucosidase inhibitors have been used in the clinic as alternative treatments for this disease. We have developed a new fluorogenic substrate for the alpha-glucosidase enzyme assay, resorufin alpha-d-glucopyranoside. The enzyme reaction product of this new substrate emits at a peak of 590 nm, reducing the interference from fluorescent compounds seen with the existing fluorogenic substrate, 4-methylumbelliferyl-alpha-D-glucopyranoside. Also, the enzyme kinetic assay can be carried out continuously without the addition of stop solution due to the lower pK(a) of the product of this substrate. Therefore, this new fluorogenic substrate is a useful tool for the alpha-glucosidase enzyme assay and will facilitate compound screening for the development of new therapies for Pompe disease.

Citing Articles

Quantification of hydrolysis activity in a biological wastewater treatment context.

Coelmont T, Van Gaelen P, Smets I Appl Microbiol Biotechnol. 2023; 107(7-8):2143-2153.

PMID: 36929187 DOI: 10.1007/s00253-023-12465-9.

Pharmacological Chaperone Therapy for Pompe Disease.

Borie-Guichot M, Lan Tran M, Genisson Y, Ballereau S, Dehoux C Molecules. 2021; 26(23).

PMID: 34885805 PMC: 8659197. DOI: 10.3390/molecules26237223.

Carnitine is a pharmacological allosteric chaperone of the human lysosomal -glucosidase.

Iacono R, Minopoli N, Ferrara M, Tarallo A, Damiano C, Porto C J Enzyme Inhib Med Chem. 2021; 36(1):2068-2079.

PMID: 34565280 PMC: 8477953. DOI: 10.1080/14756366.2021.1975694.

Second-Generation Pharmacological Chaperones: Beyond Inhibitors.

Lan Tran M, Genisson Y, Ballereau S, Dehoux C Molecules. 2020; 25(14).

PMID: 32660097 PMC: 7397201. DOI: 10.3390/molecules25143145.

Emerging Approaches for Fluorescence-Based Newborn Screening of Mucopolysaccharidoses.

Singh R, Chopra S, Graham C, Langer M, Ng R, Ullal A Diagnostics (Basel). 2020; 10(5).

PMID: 32403245 PMC: 7277946. DOI: 10.3390/diagnostics10050294.

References

Raben N, Plotz P, Byrne B . Acid alpha-glucosidase deficiency (glycogenosis type II, Pompe disease). Curr Mol Med. 2002; 2(2):145-66. DOI: 10.2174/1566524024605789. View

Reuser A, Kroos M, Willemsen R, Swallow D, Tager J, GALJAARD H . Clinical diversity in glycogenosis type II. Biosynthesis and in situ localization of acid alpha-glucosidase in mutant fibroblasts. J Clin Invest. 1987; 79(6):1689-99. PMC: 424503. DOI: 10.1172/JCI113008. View

Montalvo A, Cariati R, Deganuto M, Guerci V, Garcia R, Ciana G . Glycogenosis type II: identification and expression of three novel mutations in the acid alpha-glucosidase gene causing the infantile form of the disease. Mol Genet Metab. 2004; 81(3):203-8. DOI: 10.1016/j.ymgme.2003.11.011. View

Mahmoud A, Geslevich J, KINT J, Depuydt C, Huysse L, Zalata A . Seminal plasma alpha-glucosidase activity and male infertility. Hum Reprod. 1998; 13(3):591-5. DOI: 10.1093/humrep/13.3.591. View

Bueno C, Villegas M, Bertolotti S, Previtali C, Neumann M, Encinas M . The excited-state interaction of resazurin and resorufin with amines in aqueous solutions. Photophysics and photochemical reactions. Photochem Photobiol. 2002; 76(4):385-90. DOI: 10.1562/0031-8655(2002)076<0385:tesior>2.0.co;2. View

Martiniuk F, Chen A, Mack A, Arvanitopoulos E, Chen Y, Rom W . Carrier frequency for glycogen storage disease type II in New York and estimates of affected individuals born with the disease. Am J Med Genet. 1998; 79(1):69-72. DOI: 10.1002/(sici)1096-8628(19980827)79:1<69::aid-ajmg16>3.0.co;2-k. View

Porter W, Jennings Jr C, Wilson H . Measurement of alpha-glucosidase activity in serum from patients with cystic fibrosis or pancreatitis. Clin Chem. 1986; 32(4):652-6. View

Okumiya T, Kroos M, Van Vliet L, Takeuchi H, van der Ploeg A, Reuser A . Chemical chaperones improve transport and enhance stability of mutant alpha-glucosidases in glycogen storage disease type II. Mol Genet Metab. 2006; 90(1):49-57. DOI: 10.1016/j.ymgme.2006.09.010. View

Parenti G, Zuppaldi A, Gabriela Pittis M, Rosaria Tuzzi M, Annunziata I, Meroni G . Pharmacological enhancement of mutated alpha-glucosidase activity in fibroblasts from patients with Pompe disease. Mol Ther. 2007; 15(3):508-14. DOI: 10.1038/sj.mt.6300074. View

10.

Hultberg B, Sjoblad S, OCKERMAN P . Glycosidases in human skin fibroblast cultures. Alpha-fucosidase, alpha-galactosidase, alpha-glucosidase, beta-mannosidase, and N-acetyl-alpha-glucosaminidase. Acta Paediatr Scand. 1975; 64(1):123-31. View

11.

Simeonov A, Jadhav A, Thomas C, Wang Y, Huang R, Southall N . Fluorescence spectroscopic profiling of compound libraries. J Med Chem. 2008; 51(8):2363-71. DOI: 10.1021/jm701301m. View

12.

Okumiya T, Keulemans J, Kroos M, van der Beek N, Boer M, Takeuchi H . A new diagnostic assay for glycogen storage disease type II in mixed leukocytes. Mol Genet Metab. 2005; 88(1):22-8. DOI: 10.1016/j.ymgme.2005.10.016. View

13.

Parzefall W, Berger W, Kainzbauer E, Teufelhofer O, Schulte-Hermann R, Thurman R . Peroxisome proliferators do not increase DNA synthesis in purified rat hepatocytes. Carcinogenesis. 2001; 22(3):519-23. DOI: 10.1093/carcin/22.3.519. View

14.

Inglese J, Auld D, Jadhav A, Johnson R, Simeonov A, Yasgar A . Quantitative high-throughput screening: a titration-based approach that efficiently identifies biological activities in large chemical libraries. Proc Natl Acad Sci U S A. 2006; 103(31):11473-8. PMC: 1518803. DOI: 10.1073/pnas.0604348103. View

15.

Hays W, Wheeler D, Eghtesad B, Glew R, Johnston D . Expression of cytosolic beta-glucosidase in guinea pig liver cells. Hepatology. 1998; 28(1):156-63. DOI: 10.1002/hep.510280121. View

16.

Coleman D, Studler M, Naleway J . A long-wavelength fluorescent substrate for continuous fluorometric determination of cellulase activity: resorufin-beta-D-cellobioside. Anal Biochem. 2007; 371(2):146-53. DOI: 10.1016/j.ab.2007.08.027. View

17.

Hermans M, van Leenen D, Kroos M, Beesley C, van der Ploeg A, Sakuraba H . Twenty-two novel mutations in the lysosomal alpha-glucosidase gene (GAA) underscore the genotype-phenotype correlation in glycogen storage disease type II. Hum Mutat. 2003; 23(1):47-56. DOI: 10.1002/humu.10286. View

18.

Guerin J, Ali H, ROLLET J, Souchier C, CZYBA J . Alpha-glucosidase as a specific epididymal enzyme marker. Its validity for the etiologic diagnosis of azoospermia. J Androl. 1986; 7(3):156-62. DOI: 10.1002/j.1939-4640.1986.tb00901.x. View

19.

Walker J, Winder J, Kellam S . High-throughput microtiter plate-based chromogenic assays for glycosidase inhibitors. Appl Biochem Biotechnol. 1993; 38(1-2):141-6. DOI: 10.1007/BF02916417. View

20.

Mazura P, Fohlerova R, Brzobohaty B, Kiran N, Janda L . A new, sensitive method for enzyme kinetic studies of scarce glucosides. J Biochem Biophys Methods. 2006; 68(1):55-63. DOI: 10.1016/j.jbbm.2006.03.018. View